ArticleMediators of inflammation2025
Restoration of Immune Homeostasis: The Role of miR-30b-5p and Notch Signaling in Uveitis After Treatment With Longdan Xiegan Decoction.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveitis is an inflammatory eye disease, and Longdan Xiegan Decoction (LXD) has been used to treat uveitis. However, the underlying mechanisms have not fully been addressed. The present study aimed to provide new insights into LXD ameliorating inflammatory response of experimental autoimmune uveitis (EAU) and regulating T helper (Th) cell differentiation via the interaction between microRNA (miRNA) and mRNA. The hub genes, corresponding miRNAs, and bioactive substances from the LXD formula that are involved in ameliorating uveitis were identified through the network pharmacology analysis. We investigated the efficacy of LXD on the pathogenesis of EAU in vivo using the Genesis-D camera and histopathological examination, and confirmed the inhibitory effect of miR-30b-5p on the Notch signaling pathway in vitro. The analysis results indicated that T-cell lineage commitment and the Notch signaling pathway activation are the primary inflammatory process associated with the therapeutic effects of LXD on uveitis. Further predictions revealed the miRNA-mRNA interactions between miR-30b-5p and the mRNAs associated with Notch1 and DLL4. The pathogenesis of uveitis involves elevated Notch1, DLL4, IL-17A, and RORγt, and decreased levels of miR-30b-5p. LXD can enhance miR-30b-5p expression, inhibit Notch signaling activation, and suppress the commitment of uveitogenic T-cell lineages. Additionally, it downregulates proinflammatory cytokines while upregulating antiinflammatory cytokines, thereby promoting the the expansion of Treg and Th2 cell lineages, and restoring the ratios of Th1/Th2 and Th17/Treg cells. Reduced expression of miR-30b-5p contributes to the pathogenesis of uveitis. LXD exhibited an inhibitory effect on Notch signaling activation through the miR-30b-5p upregulation and the regulation of the balance between Th1/Th2 and Th17/Treg cell differentiation, ultimately facilitating the treatment of uveitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.